2018
Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma
Lee NCJ, Kelly JR, Park HS, An Y, Judson BL, Burtness BA, Husain ZA. Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. Oral Oncology 2018, 85: 35-39. PMID: 30220317, DOI: 10.1016/j.oraloncology.2018.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCarcinoma, Squamous CellCombined Modality TherapyFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeck DissectionNeoplasm MetastasisNeoplasm Recurrence, LocalOropharyngeal NeoplasmsPapillomavirus InfectionsProgression-Free SurvivalProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSalvage TherapyConceptsProgression-free survivalInvolved lymph nodesDistant metastasisPatterns of failureLocoregional recurrenceLymph nodesHuman papillomavirus-positive oropharyngeal carcinomaMultivariate analysisEdition American Joint CommitteeRate of DMWorse progression-free survivalHigh DM rateDedicated clinical trialsAmerican Joint CommitteeCancer (AJCC) staging systemProportional hazards regressionExternal beam radiationOropharynx cancerFree survivalNeck dissectionOropharyngeal carcinomaOverall survivalDisease recurrenceIntraoperative brachytherapyOPC patients
2017
KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Shekar T, Brown H, Cheng J, Siu L. KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Journal Of Clinical Oncology 2017, 35: tps6090-tps6090. DOI: 10.1200/jco.2017.35.15_suppl.tps6090.Peer-Reviewed Original ResearchBlinded independent central reviewConcomitant chemoradiotherapyRECIST v1.1LA-HNSCCP16-positive oropharyngeal cancerPrimary efficacy end pointRecurrent/metastatic HNSCCNeck squamous cell carcinomaDefinitive concomitant chemoradiotherapyECOG PS 0Efficacy end pointOutcome of ptsP16 negative HNSCCEvent-free survivalHalf of patientsSquamous cell carcinomaEnd of treatmentIndependent central reviewQuality of lifeMeasurable diseaseAdvanced diseaseCTCAE v4.0Primary surgeryAdvanced headNeck dissection
2016
Proposing prognostic thresholds for lymph node yield in clinically lymph node‐negative and lymph node‐positive cancers of the oral cavity
Kuo P, Mehra S, Sosa JA, Roman SA, Husain ZA, Burtness BA, Tate JP, Yarbrough WG, Judson BL. Proposing prognostic thresholds for lymph node yield in clinically lymph node‐negative and lymph node‐positive cancers of the oral cavity. Cancer 2016, 122: 3624-3631. PMID: 27479645, DOI: 10.1002/cncr.30227.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseOral cavity cancerMortality hazard ratioLymph nodesHazard ratioNeck dissectionLymph node-negative cancersLymph node-positive cancersNode-positive cancersNode-positive cohortPositive lymph nodesTherapeutic neck dissectionEnd Results (SEER) databaseLymph node yieldHigh-volume centersExtensive neck dissectionMultiple cancer sitesNode-negative cancersOverall survivalHigher lymphPrognostic factorsTreatment guidelinesNode yieldResults databaseSurgical managementPretreatment predictors of adjuvant chemoradiation in patients receiving transoral robotic surgery for squamous cell carcinoma of the oropharynx: a case control study
Subramanian HE, Park HS, Barbieri A, Mahajan A, Judson BL, Mehra S, Yarbrough WG, Burtness BA, Husain ZA. Pretreatment predictors of adjuvant chemoradiation in patients receiving transoral robotic surgery for squamous cell carcinoma of the oropharynx: a case control study. Cancers Of The Head & Neck 2016, 1: 7. PMID: 31093337, PMCID: PMC6460847, DOI: 10.1186/s41199-016-0008-7.Peer-Reviewed Original ResearchTransoral robotic surgeryPositive lymph nodesPreoperative patient characteristicsLymph node sizePositive surgical marginsExtracapsular extensionLymph nodesPatient characteristicsSurgical marginsAdjuvant chemoradiationNeck dissectionIndependent predictorsPositive marginsLymph node extracapsular extensionSingle-institution retrospective studyNode sizeLogistic regressionRobotic surgeryNodal extracapsular extensionPreoperative lymph nodeEarly-stage diseaseMajority of patientsSquamous cell carcinomaCase-control studyPrimary oropharyngeal cancer
2014
E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).
Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). Journal Of Clinical Oncology 2014, 32: lba6006-lba6006. DOI: 10.1200/jco.2014.32.18_suppl.lba6006.Peer-Reviewed Original ResearchClinical complete responseOropharyngeal squamous carcinomaLate grade 3 toxicityPost-treatment neck dissectionStage III/IVAHigh tumor control ratesGrade 3 toxicityWeek x 3Tumor control rateHuman papilloma virusLate toxicityPrimary endpointCurrent smokersComplete responseNeck dissectionNodal stageSquamous carcinomaControl ratePapilloma virusC-IMRTT1-3Weekly schedulePFSInvolved nodesDose
2013
Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression
Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge JA. Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression. Thyroid 2013, 23: 1099-1105. PMID: 23421588, PMCID: PMC3770240, DOI: 10.1089/thy.2013.0027.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAutoantibodiesBiomarkersCarcinomaCarcinoma, PapillaryDisease ProgressionFemaleHumansKaplan-Meier EstimateLogistic ModelsLymph NodesLymphatic MetastasisMaleMiddle AgedMultivariate AnalysisNeck DissectionNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhiladelphiaProportional Hazards ModelsRadiotherapy, AdjuvantReoperationRetrospective StudiesRisk FactorsThyroglobulinThyroid Cancer, PapillaryThyroid NeoplasmsThyroidectomyTime FactorsTreatment OutcomeYoung AdultConceptsComplete biochemical responseMetastatic papillary thyroid carcinomaSystemic disease progressionPapillary thyroid carcinomaExtranodal extensionDisease progressionRAI administrationUntreated patientsNeck dissectionTumor persistenceT4 classificationThyroid carcinomaLong-term clinical outcomesPresence of ENECenter cohort studyGross residual diseaseRadioactive iodine treatmentTherapeutic neck dissectionAnti-thyroglobulin antibodiesRecurrence/persistenceNational Cancer InstituteSuspicious imagingDistant diseaseNodal diseasePrior surgery
2012
LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.
Burtness B, Bourhis J, Vermorken J, Dai L, Lind C, Ehrnrooth E, Cohen E. LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients. Journal Of Clinical Oncology 2012, 30: tps5599-tps5599. DOI: 10.1200/jco.2012.30.15_suppl.tps5599.Peer-Reviewed Original ResearchDisease-free survivalNeck dissectionPO QDAdvanced squamous cell cancerIrreversible ErbB family blockerAdequate bone marrowErbB family blockerStudy of afatinibSubsequent neck dissectionCompletion of chemoradiationEvidence of diseaseHigh-risk patientsSecond primary tumorsHealth-related qualityBase of tongueSquamous cell cancerRisk of recurrenceNeck cancer patientsPlatinum-based chemoradiationSalivary gland cancerConcurrent cisplatinCurative intentDefinitive chemoradiationPrior therapyStudy medication
2010
SU‐GG‐T‐178: Intensity‐Modulated Radiation Therapy (IMRT) in the Treatment of Oropharyngeal Carcinoma: Clinical Outcomes and Relation of Parotid Gland Volume with Xerostomia
Turaka A, Weinberg B, Li T, Nicos N, Burtness B, Lango M, Ridge J, Feigenberg S. SU‐GG‐T‐178: Intensity‐Modulated Radiation Therapy (IMRT) in the Treatment of Oropharyngeal Carcinoma: Clinical Outcomes and Relation of Parotid Gland Volume with Xerostomia. Medical Physics 2010, 37: 3226-3226. DOI: 10.1118/1.3468568.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyParotid gland volumeRT dosesPercent weight lossWeight lossGland volumeMedian percent weight lossUse of IMRTPG volumesFox Chase Cancer CenterGrade 3 xerostomiaAddition of chemotherapyLocoregional control rateOverall survival rateSquamous cell cancerWeeks of treatmentPatterns of failureCurative intentMedian followToxicity scoringDefinitive RTMedian doseNeck dissectionOropharyngeal carcinomaMedian age